SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 23rd, 2015 • Genspera Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2015, between GenSpera, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 23rd, 2015 • Genspera Inc • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 23, 2015, between GenSpera, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SERIES F/G] COMMON STOCK PURCHASE WARRANT GenSpera, Inc.Genspera Inc • December 23rd, 2015 • Pharmaceutical preparations
THIS [SERIES F/G] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December ___, 2015 (the “Initial Exercise Date”) and on or prior to the close of business on the _____1 anniversary of the Effective Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from GenSpera, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
WARRANT AMENDMENT AGREEMENTWarrant Amendment Agreement • December 23rd, 2015 • Genspera Inc • Pharmaceutical preparations
This Warrant Amendment Agreement (this “Agreement”), dated as of December 23, 2015, is by and between GenSpera, Inc., a Delaware corporation (the “Company”) and the undersigned holders (the “Holders”) with respect to (i) those certain Series D Common Stock Purchase Warrants (the “Series D Warrants”) issued by the Company, which Series D Warrant is exercisable until July 9, 2020 at an exercise price (the “Series D Exercise Price”) of $0.80 per share and (ii) those certain Series E Common Stock Purchase Warrants (the “Series E Warrants” and together with the Series D Warrants, the “Warrants”) issued by the Company, which Series E Warrant is exercisable until January 9, 2016 at an exercise price (the “Series E Exercise Price”) of $0.70 per share.
